Clinical Advancement Center

San Antonio, Texas 78215

2 studies enrolling now · 17 studies all time

What they study most

ADPKD, Alport Syndrome, Anemia of Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Autosomal Dominant Polycystic Kidney, Calcific Uremic Arteriolopathy, Calciphylaxis, Cardiovascular Disease, Cardiovascular Risk, Chronic Kidney Disease, Chronic Kidney Disease (CKD), Chronic Kidney Diseases

Studies at this site

• Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease — Recruiting now
• Study of WAL0921 in Patients With Glomerular Kidney Diseases — Recruiting now
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease — Recruiting now
• A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — Running, not enrolling
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels — Running, not enrolling
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo — Completed
• A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL — Completed
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) — Stopped early
• A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON — Stopped early
• Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis — Completed
• Phase 3 Study of SNF472 for Calciphylaxis — Completed
• KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD — Completed
• A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes — Status unconfirmed